Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987758 | 0.85 | HIF1A (0.63) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL30373777 | 0.83 | HIF1A (0.76) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL1134085 | 0.83 | HIF1A (0.76) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL13139979 | 0.82 | FFAR1 (0.81) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL25547419 | 0.82 | HIF1A (0.63) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL1844973 | 0.81 | MAPT (0.66) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL24097464 | 0.81 | MAPT (0.68) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL6695006 | 0.81 | MAPT (0.68) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL21035304 | 0.81 | MAPT (0.64) | MAPTMEN1KMT2AHIF1AALDH1A1 | |
| SCHEMBL19061634 | 0.80 | TAAR1 (0.55) | MAPTMEN1KMT2AHIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| EP-1758865-A1 | PYRIDINE ANALOGS AS C5A ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121095-A1 | PYRIDINE ANALOGS AS C5A ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277644-A1 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2005-12-15 | — | — | US | disclosed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277644-A1 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | C5AR2, C5AR1, C3AR1 | MAPT 4731/4885MEN1 1989/4885KMT2A 4182/4885 |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | C5AR1, C3AR1, C5AR2 | MAPT 4620/4885MEN1 904/4885KMT2A 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.